Biotechnology

Genmab A/S

Genmab A/S to release FY2026 Q1 earnings on May 7 After-Market EST, forecast revenue USD 887.38 M, EPS USD 0.2195

Genmab A/S Announces 2026 Clinical Progress Plan

Genmab A/S released FY2025 Annual Earnings on February 17 After-Market (EST), actual revenue USD 3.72 B (forecast USD 3.729 B), actual EPS USD 1.537 (forecast USD 1.8226)

Genmab A/S released FY2025 Q4 earnings on February 17 After-Market (EST), actual revenue USD 1.058 B (forecast USD 1.047 B), actual EPS USD 0.05 (forecast USD 0.3782)

Genmab A/S Reports Quarterly Earnings with EPS of $0.55

Jefferies Analyst Maintains Buy Rating for Genmab A/S with Price Target

Morgan Stanley Reiterates Genmab's 'Neutral' Rating With a $34.00 Price Target

FactSet Survey: Genmab - ADR EPS Forecast for 2026 Downgraded

Genmab A/S to Release FY2025 Earnings on February 17 After-Market (EST), Forecast Revenue USD 3.826 B, EPS USD 1.8226

Pufang Biotech's GEN1286 Clinical Trial Suspended

Genmab Reports DARZALEX Global Net Sales of $14.351 Billion in 2025

Genmab A/S epcoritamab Phase III Trial Missed Overall Survival Goal, Shares Fell

Genmab reports positive results from its EPCORE DLBCL-1 phase III trial

UBS and Barclays Maintain Buy Rating on Genmab A/S

William Blair analyst reiterates buy rating on Genmab stock

Genmab's Experimental Drug for Blood Cancer Fails to Hit Key Goal in Late-stage Study

Genmab A/S Reports Positive Results from Epcoritamab's Phase III Trial

Genmab A/S Shares Reach 52-Week High

Genmab A/S and Anthropic Collaborate on AI to Enhance R&D Processes

Genmab Expects Multiple Pivotal Trial Readouts in 2026

agilon health

Atara Biotherap

Rackspace Tech

Global Engine

Sobr Safe

Republic Power

Alpha Tech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Xometry

K&F GROWTH ACQUISITION CORP II COM USD0.0001 CL A 29/08/2031 (SUBS/RTS)

Earning Release Date

财报预告

FY2026 Q1 Earning Release Today 2026.05.07 (EST) After-Market

GMAB

Genmab reported a 25% year-on-year revenue growth in Q1 2026, reaching $896 million, driven by increased royalties and sales of its lymphoma drug EPKINLY. However, operating profit decreased to $180 million due to higher R&D and integration costs. The company announced FDA approval for EPKINLY, removing hospitalization requirements for certain patients. Despite integration challenges, Genmab aims to strengthen its position in oncology. Analysts rate GMAB stock as a Buy with a $38.00 target, while TipRanks’ AI Analyst gives it a Neutral score due to mixed financial signals.

Tip Ranks

Merus BV

Johnson & Johnson

NOVARTIS AG

Novartis AG

Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY

ABBV

LABU

Genmab reported a 25% increase in revenue to $896 million for Q1 FY26, while operating profit decreased to $180 million from $188 million. Royalty revenue rose 26% to $742 million, driven by higher sales of DARZALEX and Kesimpta. Costs of product sales increased by 55% to $65 million, primarily due to higher profit-sharing with AbbVie. Operating expenses, excluding acquisition charges, grew 25% to $606 million, reflecting investments in pipeline expansion. The FDA approved an sBLA for DLBCL, and Genmab maintained its 2026 financial guidance.

PUBT

Abbvie

Health Care Select Sector SPDR

VG Health

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million

MYGN

Denecimig (Mim8) has shown significant efficacy in reducing the annualized bleeding rate in individuals with hemophilia A, regardless of inhibitor status, according to phase 3 FRONTIER2 trial results published in NEJM. The study demonstrated that participants receiving denecimig experienced up to 99% fewer bleeding episodes compared to on-demand treatment. Denecimig, a bispecific antibody mimetic, is designed for routine prophylaxis and is currently under FDA review. The findings highlight its potential as a preventive treatment option for hemophilia A patients.

prnewswire

Myriad Genetic

Novo Nordisk AS

Defiance Daily Target 2X Long NVO ETF

17:07 ETDenecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Genmab A/S has updated its Articles of Association to enhance capital-raising and employee incentive flexibility. The company filed a Form 6-K with the SEC, allowing the board to issue new shares, employee warrants, and convertible debt until March 2029 or 2030. The share capital remains at DKK 62,350,721. This change aims to support future financing and expansion without frequent shareholder meetings. Analysts rate GMAB stock as a Buy with a $40.00 price target, while Spark's AI Analyst gives it a Neutral score due to strong financial performance but concerns over leverage and earnings quality.

Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility

Genmab A/S has announced a reduction in its share capital by DKK 1,900,000, following a decision made at the Annual General Meeting on March 19, 2026. This involves the cancellation of 1,900,000 shares with a nominal value of DKK 1 each. The updated share capital, now totaling DKK 62,350,721, will be reflected in Nasdaq's system by April 21, 2026. Genmab is a biotechnology company focused on developing innovative antibody medicines for cancer and serious diseases.

GlobeNewswire

Genmab A/S Share Capital Reduction

Genmab A/S (OTCMKTS:GNMSF) shares fell 5.9% to $280.85, with trading volume down 87% from average levels. The company reported Q1 earnings of $0.55 per share, missing estimates of $3.10, despite revenue of $1.06 billion. Genmab specializes in antibody therapeutics for cancer treatment and has a market cap of $17.29 billion. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investments.

Market Beat

Genmab A/S (OTCMKTS:GNMSF) Trading Down 5.9%  - What's Next?

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News

StockTitan

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News

Genmab A/S announced that Orbis Investment Management Limited has become a major shareholder, holding 5.01% of the company's shares as of March 31, 2026. This disclosure highlights increasing institutional interest in Genmab, potentially boosting investor confidence in its antibody-focused pipeline. While the filing does not change daily operations, it may influence future governance and market perception. The latest analyst rating for GMAB stock is a Hold with a price target of $28.00, reflecting strong financial performance but concerns over leverage and earnings quality.

Genmab Discloses Orbis as New 5% Major Shareholder

Genmab A/S(GMAB.US)

Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY

Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million

17:07 ETDenecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility

Genmab A/S Share Capital Reduction

Genmab A/S (OTCMKTS:GNMSF) Trading Down 5.9% - What's Next?

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News

Genmab Discloses Orbis as New 5% Major Shareholder

Trending